| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.9 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |